News | May 06, 2026
Pfizer powers ahead in 2026 with strong Q1 results as pipeline momentum builds
The pharmaceutical giant reported $14.5 billion in revenue, up 5% year-over-year, and reaffirmed its full-year outlook
The pharmaceutical giant reported $14.5 billion in revenue, up 5% year-over-year, and reaffirmed its full-year outlook
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
The latest addition, a new API facility in Morrisville, North Carolina, will produce key components for solid dosage tablets, capsules, and RNA therapeutics
The company secured new accounts, including ACCESS-PVI trial sites, and aims to strengthen global commercialization efforts
New facility at Pusa Road expands advanced diagnostic, theranostics, and treatment-planning capabilities across oncology, cardiology, neurology, and nephrology
Precision medicine company advances Raman spectroscopy-based therapeutic drug monitoring platform for rapid, patient-specific dosing solutions
Notice of Compliance from Health Canada enables marketing authorisation for cancer biosimilar in Canadian market
Growth was supported by stronger COVID vaccine sales and expanded government supply agreements in international markets
The Committee backed the combination based on results from the CAPItello-281 Phase III trial, marking a key milestone in the regulatory pathway for AstraZeneca’s targeted therapy strategy in prostate cancer
The company’s Growth Portfolio delivered $6.2 billion in revenue
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
